Skip to main content
SpringerLink
Log in

Clinical Trials with Haematopoietic Growth Factors and Peripheral Blood Stem Cells

  • Conference paper
Lymphohaematopoietic Growth Factors in Cancer Therapy II

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 32 Accesses

Abstract

High-dose chemotherapy is potentially curative in some chemosensitive tumours and lymphomas, and a relationship between dose intensity and tumour response has been defined for several malignancies (for review see [1]). Dose intensity should be adequate to overcome a threshold dose that produces response, and the average relative dose intensity received is probably a major factor determining outcome of chemotherapy [2]. Dose escalation, however, is mostly limited by myelosuppression as well as drug-specific non-haematological organ toxicity. The risk of infections and bleeding complications requires expensive supportive care during this period. Therefore, to permit dose-intensive regimens without stem cell support and to reduce chemotherapy-associated morbidity and mortality, haematopoietic growth factor treatment has been studied by several investigators in conjunction with high-dose chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. Third Edition. Lippincott, Philadelphia 1989 pp 286–287

    Google Scholar 

  2. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987 (1):66

    Google Scholar 

  3. Neidhart J, Mangalik A, Kohler W, Stidley C, Saiki J, Duncan P, Souza L, Downing M: G-CSF stimulates recovery of granulocytes in patients receiving dose- intensive chemotherapy without bone marrow transplantation. J Clin Oncol 1989 (7/11):1685–1692

    Google Scholar 

  4. Neidhart JA, Kohler W, Stidley C, Mangalik A et al: Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol 1990 (8/10):1728–1738

    Google Scholar 

  5. Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU: Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human GM-CSF. JNCI 1990 (82):667–672

    CAS  Google Scholar 

  6. Steward WP, Scarffe JH, Dirix LY, Chang J, Radford JA, Bonnern E, Crowther D: GM-CSF after high-dose melphalan in patients with advanced colon cancer. Br J Cancer 1990 (61):749–754

    Article  PubMed  CAS  Google Scholar 

  7. Gianni AM, Bregni M, Siena SM, Orazi A, Stern AC, Gondola L, Bonadonna G: Recombinant human GM- CSF reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin’s lymphoma. J Clin Oncol 1990 (8/5):768–778

    Google Scholar 

  8. Ho AD, Del Valle F, Engelhard M, Hiddemanns W, Rückle H: Mitoxantrone/high-dose Ara C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin’s lymphoma: a pilot study. Cancer 1990 (66):423

    Google Scholar 

  9. Sronchud MH, Howell A, Crowther D et al: The use of G-CSF to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989 (60):121–125

    Article  Google Scholar 

  10. Ganser A, Lindemann A, Seipelt G et al: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990 (76):666–676

    PubMed  CAS  Google Scholar 

  11. Lindemann A, Ganser F, Herrmann F et al: Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 1991 (9):2120–2127

    PubMed  CAS  Google Scholar 

  12. Zeidler C, Souza L, Welte K: In vivo effects of interleukin-6 on hematopoiesis in primates. Blood 1989 (74):154a

    Google Scholar 

  13. Patchen ML, MacVittie TJ, Williams JL et al: Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation induced hematopoietic depression. Blood 1991(77):472–480

    PubMed  CAS  Google Scholar 

  14. Bridell RA, Bruno E, Cooper FJ: The effect of interleukin-11 on in vitro human megakaryocytopoiesis. Blood 1990 (76):448a

    Google Scholar 

  15. Burstein SA, Mei R, Henvthorn J: Recombinant human leukemia inhibitory factor (LIF) and interleukin-11 promote murine and human megakaryocytopoiesis in vitro. Blood 1990 (76):450a

    Google Scholar 

  16. Metealf D, Nicola NA, Gearing DP: Effect of injected leukemia inhibitory factor on hematopoietic and other tissue in mice. Blood 1991 (76):50

    Google Scholar 

  17. Zeidler C, Kanz L, Pietsch T, Boone T, Samal B, Welte K: Leukemia inhibitory factor (LIF) induces thrombocytosis in primates. Blood 1990 (76):174a

    Google Scholar 

  18. Richman CM, Weiner RS, Yankee RA: Increase in circulating stem cells following chemotherapy in man. Blood 1976 (47): 1031

    Google Scholar 

  19. Abrams RA, Mc-Cormack K, Bowles C, Deisseroth AB: Cyclophosphamide treatment expands the circulating haemopoietic stem cell pool in dogs. J Clin Invest 1981 (67):1392

    Google Scholar 

  20. To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp L, Dale BM, Dart GW, Roberts MM, Sage RE: Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1989 (19):442

    Google Scholar 

  21. Haas R, Ho AD, Bredthauer U, Cayeux S, Egerer G, Knauf W, Hunstein W: Successful autologous transplantation of blood stem cells mobilized with rhGM-CSF. Exp Hematol 1990 (18):94

    Google Scholar 

  22. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD: GM-CSF expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988 (May 28 ): 1194

    Google Scholar 

  23. Villeval JL, Dührsen U, Morstyn G, Metealf D: Effect of recombinant human GM-CSF on progenitor cells in patients with advanced malignancies. Br J Hematol 1990 (74):36

    Google Scholar 

  24. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metealf D: Effects of recombinant human G-CSF on hematopoietic progenitor cells in cancer patiens. Blood 1988 (72): 2074

    Google Scholar 

  25. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989 (ii):580–585

    Article  Google Scholar 

  26. Kessinger A, Armitage JO: The evolving role of autologous peripheral stem cell transplantation following high-dose chemotherapy for malignancies. Blood 1991 (77/2):211–213

    Google Scholar 

  27. Körbling M, Holle R, Haas R, Knauf W, Dörken B, Ho AD, Kuse R, Pralle H, Fliedner TM, Hunstein W: Autologous blood stem-cell transplantation in patients with advanced Hodgkins disease and prior radiation to the pelvic site. J Clin Oncol 1990 (8):978–985

    PubMed  Google Scholar 

  28. Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weisenburger DD: High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989 (74): 1260

    Google Scholar 

  29. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gondola L, Stern AC, Landsdorp PM, Bonadonna G, Gianni AM: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991 (77):400

    Google Scholar 

  30. Stiff PJ, Koester AR, Eagleton IE, Hindman T, Bruad E: Autologous stem cell transplantation using peripheral blood stem cells. Transplantation 1987 (44):585

    Google Scholar 

  31. Juttner CA, To LB, Ho JQK: Early lympho- hematopoietic recovery after autografting using peripheral blood stem cells in acute non- lymphoblastic leukemia. Transplant Proc 1988 (20):40

    Google Scholar 

  32. Korbling M, Dorken B, Ho AD et al: Autologous transplantation of blood-derived hematopoietic stem cells after myeloablative therapy in a patient with Burkitts lymphoma. Blood 1986 (72):529–532

    Google Scholar 

  33. Kessinger A, Armitage JO, Landmark JD et al: Autologous peripheral blood stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988 (71):723–727

    PubMed  CAS  Google Scholar 

  34. To LB, Russel J, Moore S, Juttner CA: Residual leukemia cannot be detected in very early remission peripheral blood stem cell collections in acute non- lymphoblastic leukemia. Leuk Res 1987 (11):327

    Google Scholar 

  35. Moss TJ, Sandes DG, Lasky LC, Bostrom B: Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990 (75):1879–1883

    Google Scholar 

  36. Lasky LC, Ash RC, Kersey JH, Zanjani ED, McCullough J: Collection of pluripotential hematopoietic stem cells by cytapheresis. Blood 1982 (59):822

    Google Scholar 

  37. Juttner CA, To LB, Haylock DN, Cyson PG, Thorp D, Dart GW, Ho JQK, Horvath N, Bardy P: Autologous blood stem cell transplantation. Transplant Proc 1989 (21): 2929

    Google Scholar 

  38. Ghosn M, Droz JP, Theodore C: Salvage chemotherapy in refractory germ-cell tumors with etoposide (VP16) plus ifosfamide plus high-dose cisplatin. Cancer 1988 (62):24

    Google Scholar 

  39. Wolf M, Havemann K, Holle R: Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small cell lung cancer: a multicenter German randomized trial. J Clin Oncol 1987 (5): 1880

    Google Scholar 

  40. Cabanillas F, Velasquez WS, McLaughlin P: Results of recent salvage chemotherapy regimens for lymphoma and Hodgkins disease. Semin Hematol 1988 (25):47

    Google Scholar 

  41. Smith IE, Perren TJ, Ashley SA, Woodiwiss J, Forgeson GV, Yarnold JR, Ford TH: Carboplatin, etoposide and ifosfamide as intensive chemotherapy for small cell lung cancer. J Clin Oncol 1990 (8):899

    Google Scholar 

  42. Loehrer PJ: Advances in ifosfamide chemotherapy. Semin Oncol 1990(17):1

    Google Scholar 

  43. Kanz L, Lohr GW, Fauser AA: Lymphokine(s) from isolated T-lymphocyte subpopulations support multilineage hematopoietic colony (CFU-GEMM) and megakaryocyte (CFU-Meg) formation. Blood 1986 (68):991

    Google Scholar 

  44. Bross KJ, Pangalis GA, Staatz CB, Blume KG: Demonstration of cell suface antigens and their antibodies by the peroxidase anti-peroxidase method. Transplantation 1978 (25):331

    Google Scholar 

  45. Kanz L, Brugger W, Bross KJ, Frisch J, Schulz G, Mertelsmann R: IL-3 + GM-CSF induced mobilization of myeloid, erythroid, multilineage as well as megakaryocytic progenitor cells following polychemotherapy in cancer patients. Blood 1991 (78): 1222a

    Google Scholar 

  46. Brugger W, Bross KJ, Frisch J, Dem P, Weber B, Mertelsmann R, Kanz L: Mobilization of PBPC by sequential administration of IL-3 and GM-CSF following polychemotherapy with etoposide, ifosfamide and cis-platin. Blood 1992 (79/5):1193–1200

    PubMed  CAS  Google Scholar 

  47. Kanz L, Brugger W, Bross KJ, Mertelsmann R: Correlation analyses between CD34+ cells and clonogenic progenitors mobilized into the peripheral blood by IL-3 + GM-CSF following polychemotherapy in cancer patients. Int J Cell Cloning 1992 (10):68–70

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology and Oncology, Albert-Ludwigs University Medical Centre, Hugstetter Strasse 55, 7800, Freiburg, Germany

    W. Brugger, R. Mertelsmann & L. Kanz

Authors
  1. W. Brugger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Mertelsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Kanz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin I, Klinikum der Albert-Ludwigs-Universität, Hugstetter Straße 55, 7500, Freiburg, Federal Republic of Germany

    Roland Mertelsmann

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Brugger, W., Mertelsmann, R., Kanz, L. (1992). Clinical Trials with Haematopoietic Growth Factors and Peripheral Blood Stem Cells. In: Mertelsmann, R. (eds) Lymphohaematopoietic Growth Factors in Cancer Therapy II. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77801-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77801-8_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77803-2

  • Online ISBN: 978-3-642-77801-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation